Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Trust factor.

Bonnem EM.

Oncologist. 2002;7(4):383-4. No abstract available.

2.

Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.

Dehmer GJ, Lange RA, Tate DA, Pirwitz M, Daniel W, Fisher M, Bonnem EM.

Circulation. 1996 Nov 1;94(9 Suppl):II347-52.

PMID:
8901773
3.

Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma.

Belman N, Bonnem EM, Harvey HA, Lipton A.

Invest New Drugs. 1996;14(4):387-9.

PMID:
9157074
4.

Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans.

Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM.

Circulation. 1995 Apr 15;91(8):2188-94.

PMID:
7697848
5.

Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex.

Hewitt RG, Morse GD, Lawrence WD, Maliszewski ML, Santora J, Bartos L, Bonnem E, Poiesz B.

Antimicrob Agents Chemother. 1993 Mar;37(3):512-22.

6.

Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma.

Walsh C, Wernz JC, Levine A, Rarick M, Willson E, Melendez D, Bonnem E, Thompson J, Shelton B.

J Acquir Immune Defic Syndr. 1993 Mar;6(3):265-71.

PMID:
7680712
7.

Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

Gilleece MH, Scarffe JH, Ghosh A, Heyworth CM, Bonnem E, Testa N, Stern P, Dexter TM.

Br J Cancer. 1992 Jul;66(1):204-10.

8.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.

Advani R, Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, Greenberg PL.

Ann Intern Med. 1992 Feb 1;116(3):183-9.

PMID:
1345803
9.

Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.

Golomb HM, Ratain MJ, Fefer A, Thompson J, Portlock CS, Ozer H, Mick R, Chiavello J, Israel RJ, Bonnem EM.

Leuk Lymphoma. 1991;5(5-6):335-40. doi: 10.3109/10428199109067626.

PMID:
27463343
10.

Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.

Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW.

Leuk Lymphoma. 1991;4(2):99-102. doi: 10.3109/10428199109068051.

PMID:
27462938
11.
12.

High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma.

Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R.

Blood. 1990 Aug 15;76(4):677-80.

13.

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.

Steward WP, Scarffe JH, Dirix LY, Chang J, Radford JA, Bonnem E, Crowther D.

Br J Cancer. 1990 May;61(5):749-54.

14.

Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.

Lieschke GJ, Maher D, O'Connor M, Green M, Sheridan W, Rallings M, Bonnem E, Burgess AW, McGrath K, Fox RM, et al.

Cancer Res. 1990 Feb 1;50(3):606-14.

15.

Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor.

Steward WP, Scarffe JH, Bonnem E, Crowther D.

Int J Cell Cloning. 1990 Jan;8 Suppl 1:335-46.

PMID:
2182743
16.

GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS.

Grossberg HS, Bonnem EM, Buhles WC Jr.

N Engl J Med. 1989 Jun 8;320(23):1560. No abstract available.

PMID:
2542793
17.

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.

Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A.

J Clin Oncol. 1989 May;7(5):629-37.

PMID:
2651578
18.

Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.

Lieschke GJ, Maher D, Cebon J, O'Connor M, Green M, Sheridan W, Boyd A, Rallings M, Bonnem E, Metcalf D, et al.

Ann Intern Med. 1989 Mar 1;110(5):357-64.

PMID:
2644886
19.

Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.

Steward WP, Scarffe JH, Austin R, Bonnem E, Thatcher N, Morgenstern G, Crowther D.

Br J Cancer. 1989 Jan;59(1):142-5.

20.

Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days.

Dorr RT, Salmon SE, Robertone A, Bonnem E.

J Interferon Res. 1988 Dec;8(6):717-25.

PMID:
3230330
21.

A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma.

Foon K, Doroshow J, Bonnem E, Fefer A, Graham S, Grosh B, Narayan P, Elias L, Harvey H, Schulof R, et al.

J Biol Response Mod. 1988 Dec;7(6):540-5.

PMID:
3145964
22.

Phase I study of recombinant gamma-interferon (rIFN-gamma).

Boman BM, Gagen MM, Bonnem E, Ajani JA, Schmidt S, Dimery IW, Golando J, Neidhart J.

J Biol Response Mod. 1988 Oct;7(5):438-46.

PMID:
3141591
23.

Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.

Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnem E, et al.

Semin Oncol. 1988 Oct;15(5 Suppl 5):7-9. No abstract available.

PMID:
3057646
24.

Granulocyte macrophage colony stimulating factor (GM-CSF) current status and future development.

Bonnem EM, Morstyn G.

Semin Oncol. 1988 Oct;15(5 Suppl 5):46-51. Review. No abstract available.

PMID:
3057644
25.

Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay.

Cebon J, Dempsey P, Fox R, Kannourakis G, Bonnem E, Burgess AW, Morstyn G.

Blood. 1988 Oct;72(4):1340-7.

26.

Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia.

Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Bonnem E, et al.

J Natl Cancer Inst. 1988 May 4;80(5):369-73.

PMID:
3282078
27.

The therapy of multiple myeloma with the interferons.

Bonnem EM.

Cancer Treat Rev. 1988 Jan;15 Suppl A:35-41. Review. No abstract available.

PMID:
2449280
28.

Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma.

Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlock C, Myers JW, Kisner D, Norred S, Spiegel RJ, Bonnem EM.

Semin Oncol. 1987 Jun;14(2 Suppl 2):18-23. No abstract available.

PMID:
3589702
29.

Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.

Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnem EM, et al.

Semin Oncol. 1987 Jun;14(2 Suppl 2):13-7.

PMID:
3589701
30.

Alfa interferon: combinations with other antineoplastic modalities.

Bonnem EM.

Semin Oncol. 1987 Jun;14(2 Suppl 2):48-60. Review.

PMID:
3296212
31.

Gamma-interferon: physiology and speculation on its role in medicine.

Bonnem EM, Oldham RK.

J Biol Response Mod. 1987 Jun;6(3):275-301. Review.

PMID:
3110378
32.

A phase I clinical trial of recombinant DNA gamma interferon.

Brown TD, Koeller J, Beougher K, Golando J, Bonnem EM, Spiegel RJ, Von Hoff DD.

J Clin Oncol. 1987 May;5(5):790-8.

PMID:
3106584
33.

A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.

Elias L, Hoffman R, Boswell S, Tensen L, Bonnem EM.

Leukemia. 1987 Feb;1(2):105-10.

PMID:
3478534
34.

Alpha interferon: a look to the future.

Bonnem EM.

Invest New Drugs. 1987;5 Suppl:S65-75. Review.

PMID:
3298135
35.

Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects.

Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A.

Cancer Immunol Immunother. 1987;25(1):47-53.

PMID:
3109737
36.

Phase II study of rDNA alpha-2 interferon (INTRON A) in patients with multiple myeloma utilizing an escalating induction phase.

Case DC Jr, Sonneborn HL, Paul SD, Hiebel J, Boyd MA, Shepp MA, Dorsk BM, Bonnem E.

Cancer Treat Rep. 1986 Nov;70(11):1251-4.

PMID:
3768870
37.

The combined use of interferon and radiotherapy in cancer management.

Torrisi J, Berg C, Bonnem E, Dritschilo A.

Semin Oncol. 1986 Sep;13(3 Suppl 2):78-83.

PMID:
3764443
38.

Phase I combined modality clinical trial of alpha-2-interferon and radiotherapy.

Torrisi J, Berg C, Harter K, Lvovsky E, Yeung K, Woolley P, Bonnem E, Dritschilo A.

Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1453-6.

PMID:
3759573
39.

Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma.

Harvey J, Bonnem E, Grady K, Goodman A, Schein P.

Med Pediatr Oncol. 1985;13(1):30-1.

PMID:
3969059
40.

Interferon-alpha: current status and future promise.

Bonnem EM, Spiegel RJ.

J Biol Response Mod. 1984 Dec;3(6):580-98. Review. No abstract available.

PMID:
6392483
41.

Methotrexate-induced immune haemolytic anaemia.

Woolley PV 3rd, Sacher RA, Priego VM, Schanfield MS, Bonnem EM.

Br J Haematol. 1983 Aug;54(4):543-52.

PMID:
6871106
42.

Phase II trial of mitoxantrone in advanced colorectal cancer.

Bonnem EM, Mitchell EP, Woolley PV, Smith FP, Neefe J, Smith L, Schein PS.

Cancer Treat Rep. 1982 Nov;66(11):1995-6. No abstract available.

PMID:
7139642
43.

Platinum concentrations in human glioblastoma multiforme following the use of cisplatin.

Bonnem EM, Litterst CL, Smith FP.

Cancer Treat Rep. 1982 Aug;66(8):1661-3.

PMID:
6286121
44.

Elevated prostaglandin e in idiopathic intestinal pseudo-obstruction.

Luderer JR, Demers LM, Bonnem EM, Saleem A, Jeffries GH.

N Engl J Med. 1976 Nov 18;295(21):1179. No abstract available.

PMID:
980023
45.

Macromerine, normacromerine and bisnormacromerine: non-psychoactive methylated derivatives of norepinephrine.

Vogel WH, Evans BD, Bonnem EM, Fischer JF, McLaughlin JL.

Psychopharmacologia. 1973 May 21;30(2):145-51. No abstract available.

PMID:
4711372

Supplemental Content

Loading ...
Support Center